ICL Invests in Breakthrough Sustainable Protein Ingredients Startup Arkeon
ICL (NYSE: ICL, TASE: ICL), a global specialty minerals company, has announced a €2.75 million investment in Arkeon, GmbH through its ICL Planet Startup Hub. This funding will advance Arkeon's carbon dioxide conversion technology, enabling the production of customizable protein ingredients. Arkeon utilizes a one-step fermentation process, turning CO2 into essential amino acids sustainably. ICL aims to support Arkeon's growth in creating clean-label proteins that have a minimal ecological footprint. This investment marks ICL's third in the past year, strengthening its commitment to innovation in the FoodTech and AgriTech sectors.
- €2.75 million investment in Arkeon supports innovative sustainable protein production.
- ICL's partnership with Arkeon aligns with its growth strategy in alternative proteins.
- Access to advanced R&D labs and production facilities for Arkeon to scale operations.
- None.
Companies partnering to develop CO2-derived protein ingredients for food applications, using Arkeon’s carbon conversion process
Arkeon’s patented process pioneered the harnessing of carbon dioxide to make protein – through the use of archaea, a highly resilient single-celled microorganism – without genetic engineering. Archaea, part of the microbiota of all organisms, naturally feeds on CO2 and transforms these environmental emissions into nutritious protein – meaning the process is not just sustainable, it is also regenerative.
“I dedicated much of the past decade to exploring new and sustainable biotechnological methods of alternative protein production,” said
“Arkeon has achieved a major breakthrough, by finding a way to nourish people and revitalize our ecosystems at the same time,” said
“Although a young company, Arkeon brings to the table innovative and sustainable technology for use in creating the next generation of alternative protein products. They also fully align with ICL Food Specialties growth strategy of pursuing new frontiers in unique and functional alternative proteins,” added
ICL is leading the current SAFE investment round, which totals more than
About ICL
For more information, visit ICL's website at www.icl-group.com.
To access ICL's interactive ESG report, please click here.
You can also learn more about ICL on Facebook, LinkedIn and Instagram.
About
Arkeon is an ingredients company, based in
For more information, visit www.arkeon.bio.
Press information available at press@arkeon.bio and arkeon.bio/press.
Forward Looking Statements
This announcement contains statements that constitute forward‑looking statements, many of which can be identified by the use of forward‑looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others.
Forward-looking statements appear in this press release and include, but are not limited to, statements regarding the company’s intent, belief or current expectations. Forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to: estimates, forecasts and statements as to management's expectations with respect to, among other things, business and financial prospects, financial multiples and accretion estimates, future trends, plans, strategies, positioning, objectives and expectations, general economic, market and business conditions, supply chain and logistics disruptions, energy storage and electric vehicle growth, the potential for new COVID-19 variants, global unrest and conflict, governmental and regulatory requirements and actions by governmental authorities, including changes in government policy, changes in environmental, tax and other laws or regulations and the interpretation thereof. As a result of the foregoing, readers should not place undue reliance on the forward‐looking statements contained in this press release concerning the timing of the transaction, or other more specific risks and uncertainties facing ICL, such as those set forth in the “Risk Factors” section of its Annual Report on Form 20-F filed on
Forward-looking statements refer only to the date they are made, and the company does not undertake any obligation to update them in light of new information or future developments or to publicly release any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005879/en/
Investor and Press Contact – Global
VP, Global Investor Relations
+1-314-983-7665
Peggy.ReillyTharp@icl-group.com
Investor and Press Contact -
Spokesperson and IR Representative
+972-3-6844459
Adi.Bajayo@icl-group.com
Source:
FAQ
What recent investment did ICL announce?
What is Arkeon's technology for protein production?
How does ICL plan to support Arkeon?
How does this investment align with ICL's strategy?